Bristol-Myers CEO's 2009 compensation down 22 pct

2010-03-09T16:00:53Z

<div id="subtitle">2009 compensation for Bristol-Myers Squibb CEO Cornelius falls 22 percent amid recession</div><div><p>The chief executive of drugmaker Bristol-Myers Squibb Co., James Cornelius, received a 2009 compensation package valued by The Associated...

Bristol-Myers: 60 drugs in testing to boost sales

2010-03-05T08:01:06Z

<div><p>Executives at Bristol-Myers Squibb Co. told analysts Thursday at a business briefing that the drugmaker has 60 potential drugs in development, seven in late-stage studies, and plenty of money for dealmaking.</p><p>"Five potential new medicines could be introduced in the next three years," said Dr. Elliot Sigal, head of res...

A look at key Bristol-Myers drugs in late testing

2010-03-04T15:00:11Z

<div id="subtitle">Key Bristol-Myers drugs in development target cancer types, transplants, heart disease</div><div><p>Some key experimental drugs in late-stage testing by biopharmaceutical company Bristol-Myers Squibb Co.:</p><p>_ipilimumuab, for melanoma, the most dangerous type of skin cancer. Data from a late-stage study could be presented at a major cancer meeting in J...

Bristol-Myers post-Plavix outlook exceeds views

2010-03-04T09:00:47Z

<div id="subtitle">Bristol-Myers expects profit of at least $1.95 a share in 2013, first full year without Plavix</div><div><p>Drugmaker Bristol-Myers Squibb Co. said Thursday it expects a profit of at least $1.95 per share in 2013, a crucial period because that's when U.S. generic com...

Bristol sets baseline for profits post-Plavix

2010-03-04T05:45:38Z

<div><p>NEW YORK (Reuters) - Bristol-Myers Squibb Co <BMY.N> set a better-than-expected baseline for profits in 2013 as it provided investors their first glimpse of life after Plavix, the second-largest selling drug in the world.</p><p>Bristol ...

Bristol-Myers, Allergan in $413M pain drug deal

2010-03-03T07:00:12Z

<div id="subtitle">Bristol-Myers Squibb could pay Allergan $413M in licensing deal for neuropathic pain drug</div><div><p>Bristol-Myers Squibb and Allergan will jointly attempt to develop a drug to treat chronic pain from tissue damage, the drugmakers said Wednesday.</p><p>The agreement could eventually be worth $413...

Bristol-Myers CEO to retire; COO to succeed him

2010-03-02T15:00:41Z

<div id="subtitle">Bristol-Myers' Cornelius to retire as CEO, but still head board; COO Andreotti to succeed him</div><div><p>Drugmaker Bristol-Myers Squibb Co. said Tuesday its chief executive will retire in May and be succeeded by the current chief operating officer.</p><p>The move is the fourth official retirement from a senior health company executive position for

Bristol Myers CEO

2010-03-02T14:46:26Z

In this photo released by Bristol-Myers Squibb Co., newly named CEO Lamberto Andreotti is shown. The drugmaker on Tuesday, March 2, 2010 said Andreotti will serve as CEO effective May 4, when current chairman and CEO James M. Cornelius will retire. (AP Photo/Bristol-Myers Squibb, <...

FDA has concerns with Bristol transplant drug

2010-02-25T09:17:38Z

<div id="subtitle">FDA says Bristol-Myers kidney transplant drug extends life, but carries side effects</div><div><p>The Food and Drug Administration said Thursday an organ transplant drug from Bristol-Myers Squibb Co. improves kidney function, but also appears to carry potentially fatal side effect...

Bristol-Myers Squibb to freeze salaries in 2010

2010-02-22T11:18:34Z

<div id="subtitle">Bristol-Myers Squibb says it will stop all non-mandated salary raises in 2010 to cut costs</div><div><p>Drugmaker Bristol-Myers Squibb Co. says it is freezing employee salaries for 2010 as it cuts spending and prepares for a drop in sales of its blockbuster blood thinner Plavix.</p&...

Drugmaker employee in NY charged with trade theft

2010-02-22T12:07:28Z

<div id="subtitle">Bristol-Myers-Squibb employee in upstate New York accused of stealing trade secrets</div><div><p>A fired Bristol-Myers-Squibb Co. employee stole trade secrets from the drugmaker in a plot to la...

Drugmakers post higher sales but a mix on profits

2010-02-22T13:46:12Z

<div><p>Fourth-quarter revenues climbed about 10 percent for major drugmakers AstraZeneca PLC, Bristol-Myers Squibb Co. and Eli Lilly &amp; Co., mainly buoyed by sales of drugs for heart disease, depression and other mental illnesses.&a...

Bristol-Myers 4Q profit rises on sales boost, gain

2010-02-22T13:54:48Z

<div id="subtitle">Bristol-Myers 4th-qtr profit rises on higher sales of key drugs, gain from Mead Johnson sale</div><div><p>Stronger sales of nearly all its medicines and a multibillion-dollar, one-time gain bro...

Bristol-Myers forecasts big jump in EPS for 2010

2010-02-22T13:52:20Z

<div id="subtitle">Drugmaker Bristol-Myers Squibb sees jump in 2010 profit to range of $1.94 to $2.04 per share</div><div><p>Drugmaker Bristol-Myers Squibb Co. said Thursday that it expects earnings per share this year to range from $1.94 to $2.04.</p><p>The maker of blockbuster blood thinner Bristol-Myers Squibb's blood thinner medication Plavix is shown in New York. Stronger sales of nearly all its medicines and a multibillion-dollar, one-time gain brought drugmaker Bristol-Myers Squibb Co. a huge jump in fourth-quarter profit, the company said Thursday, Jan. 28, 2...

Bristol-Myers, now a pure pharma, to post results

2010-02-22T14:36:48Z

<div id="subtitle">Bristol-Myers Squibb, after nutrition business sale, has new pure pharma focus, $8B for deals</div><div><p>Bristol-Myers Squibb Co., the world's No. 15 drugmaker by revenue, reports fourth-quarter earnings Thursday. The following is a summary of key developments and analyst opinion related to the period.</p><p&...

Bristol-Myers spent $953K lobbying gov't in 3Q

2010-02-23T11:51:33Z

<div id="subtitle">Bristol-Myers Squibb spent $953,000 lobbying on drug pricing, health overhaul in third quarter</div><div><p>Pharmaceutical company Bristol-Myers Squibb Co. spent $953,000 lobbying on drug pricing and access, health care and patent reform in the third quarter, according to a quarterly disclosure form.</p><p>T...

Bristol-Myers cuts outlook after Mead split

2010-02-23T12:05:03Z

<div id="subtitle">Bristol-Myers Squibb cuts 2009 profit outlook following Mead Johnson holdings split</div><div><p>Drug developer Bristol-Myers Squibb Co. cut its 2009 profit outlook Wednesday after completing a split off of its Mead Johnson Nutrition Co. holdings.<...

Bristol-Myers declares dividend of 32 cents

2010-02-23T12:54:25Z

<div id="subtitle">Bristol-Myers lifts dividend to 32 cents from 31 cents, dividend is payable paid Feb. 1</div><div><p>Drugmaker Bristol-Myers Squibb Co. said Monday it raised its quarterly dividend by a penny, to 32 cents from 31 cents.</p><p>The dividend is payable Feb. 1, 2010, to shareholders of record as of Jan. 4. Brist...

Bristol-Myers says Mead Johnson offer overbooked

2010-02-23T14:08:59Z

<div id="subtitle">Bristol-Myers Squibb says Mead Johnson stock offer was oversubscribed</div><div><p>Drugmaker Bristol-Myers Squibb Co. said Friday its offer to exchange shares of baby formula maker Mead Johnson Nutrition Co. for shares of its own stock was oversubscribed....

News on Bristol-Myers Squibb Company